Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology's stock has experienced fluctuations due to recent financial announcements and clinical trial updates. The stock has increased by 36.21% over the last six months and 135.71% over the last year. In Q4 2025, the company reported total revenue of $75.5 million and a net income of $13.4 million, but the stock plunged due to weaker-than-expected revenue guidance. In Q1 2026, Puma reported a net loss of $3.8 million with total revenue of $44.8 million, attributed to inventory drawdown. The company raised its full-year 2026 net NERLYNX product revenue guidance to $202 million to $206 million and net income guidance to $16 million to $19 million. Puma Biotechnology is now debt-free. Interim Phase II clinical data on alisertib demonstrated enhanced efficacy in biomarker-defined patient groups.

Puma Biotechnology operates in the biopharmaceutical industry, which is generally not considered significantly cyclical. The demand for its products, primarily NERLYNX, is driven by the stable and ongoing need for oncology treatments rather than seasonal fluctuations. The company's revenue primarily stems from product sales and royalties, which have shown steady growth in product revenue.

Puma Biotechnology, Inc. is a biopharmaceutical company based in Los Angeles, California, focused on acquiring, developing, and commercializing cancer therapeutics. Their primary product is NERLYNX (neratinib), an FDA-approved oral kinase inhibitor used in treating HER2-positive breast cancer. The company is also advancing alisertib, a selective aurora kinase A inhibitor, through Phase II clinical trials for small cell lung cancer and HER2-negative, hormone receptor-positive metastatic breast cancer.

Puma Biotechnology, Inc. is headquartered in Los Angeles, California, and has a global presence with NERLYNX approved in the United States, Europe, and over 60 other countries. The company has established international sub-licensing partnerships for commercialization rights in regions including Greater China, Israel, Canada, Southeast Asia, and Latin America. NERLYNX has recently launched in Thailand, further expanding Puma's global footprint.

Puma Biotechnology focuses on developing and commercializing innovative products to enhance cancer care, with increased demand for NERLYNX. Recent clinical data from alisertib studies have positively contributed to the company's scientific standing. In 2019, Puma Biotechnology and its CEO were found guilty of securities fraud, which was settled in August 2022. A class action complaint was filed in 2015 alleging the company misled shareholders regarding the results of a Phase III trial for neratinib and its regulatory approval timeline.

Puma Biotechnology, Inc. has 158 institutional owners and shareholders holding a total of 35,361,668 shares. Institutional ownership stands at 70.12% (35.34 million shares), while insider ownership is 17.69% (8.92 million shares). Major institutional owners include Acorn Capital Advisors, Llc, Vanguard Group Inc, and BlackRock, Inc.